MOLN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Molecular Partners AG (MOLN) is not a strong buy at the moment for a beginner investor with a long-term horizon. While the company has promising developments in its oncology pipeline and a positive analyst rating, the lack of significant financial growth, neutral trading sentiment, and absence of strong proprietary trading signals suggest waiting for more favorable conditions or clearer growth trends.
The technical indicators show a bullish trend with MACD positively expanding, RSI in the neutral zone, and moving averages aligned bullishly (SMA_5 > SMA_20 > SMA_200). However, the stock's near-term trend suggests a 40% chance of a slight decline in the next day (-0.83%) and week (-3.18%), with potential recovery in the next month (+4.28%).
Molecular Partners has introduced innovative oncology candidates like MP0632 and MP0712, showing promising preclinical results in tumor regression and safety. The company is advancing its DARPin platform, which could address unmet needs in oncology.
The company has no significant revenue growth (0% YoY) and continues to report negative net income (-$12.65M in Q4 2025). Gross margin dropped to 0, indicating no profitability. Trading sentiment from hedge funds and insiders remains neutral, and there is no recent congress trading data.
In Q4 2025, revenue remained stagnant at $0 (0% YoY), net income improved slightly but remained negative at -$12.65M (+12.62% YoY), and EPS increased to -0.34 (+13.33% YoY). Gross margin dropped to 0, reflecting no profitability.
H.C. Wainwright initiated coverage with a Buy rating and a $13 price target, citing the company's diversified oncology pipeline and DARPin platform. This indicates optimism for long-term growth potential.
